Liver Fibrosis AssaysHelp improve the assessment of NAFLD/NASH and chronic liver disease patients at risk of disease progression

The ELF™ Test

Direct assessment of fibrosis has proven valuable for identifying patients at risk of progressing to cirrhosis and/or LREs.

Assess the risk of NAFLD/NASH progression and liver-related events with a simple blood test.

Assessing fibrosis risk with a more accessible blood test can help improve clinical and financial outcomes.

Helping to Reshape NASH Clinical Trials

Learn more about:

Videos

Hear from key opinion leaders about the rising prevalence of NAFLD/NASH and the need for non-invasive tests.

Four experts discuss how timely identification of patients at risk of progression using noninvasive diagnostic tests is crucial.

Hear from a few Siemens Healthineers colleagues working to help turn the tide against the liver's silent killer – NASH

Would you like to provide detailed feedback?

125 / 125

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

Be the first to know about our events, training and news.